AR068528A1 - Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos - Google Patents
Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismosInfo
- Publication number
- AR068528A1 AR068528A1 ARP080104110A ARP080104110A AR068528A1 AR 068528 A1 AR068528 A1 AR 068528A1 AR P080104110 A ARP080104110 A AR P080104110A AR P080104110 A ARP080104110 A AR P080104110A AR 068528 A1 AR068528 A1 AR 068528A1
- Authority
- AR
- Argentina
- Prior art keywords
- solid form
- same
- salt
- compositions
- 2theta
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 9
- 239000000203 mixture Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052802 copper Inorganic materials 0.000 abstract 3
- 239000010949 copper Substances 0.000 abstract 3
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 3
- 230000005855 radiation Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- -1 salts hydrobromide Chemical class 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 229950008913 edisilate Drugs 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 229950006327 napsilate Drugs 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99463507P | 2007-09-19 | 2007-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068528A1 true AR068528A1 (es) | 2009-11-18 |
Family
ID=40468693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104110A AR068528A1 (es) | 2007-09-19 | 2008-09-19 | Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8883783B2 (Direct) |
| EP (1) | EP2201018B1 (Direct) |
| JP (1) | JP5462168B2 (Direct) |
| KR (2) | KR101572701B1 (Direct) |
| CN (1) | CN101868465B (Direct) |
| AR (1) | AR068528A1 (Direct) |
| AU (1) | AU2008302744B2 (Direct) |
| BR (1) | BRPI0816904B8 (Direct) |
| CA (1) | CA2696776C (Direct) |
| CY (1) | CY1117583T1 (Direct) |
| DK (1) | DK2201018T3 (Direct) |
| ES (1) | ES2573292T3 (Direct) |
| HR (1) | HRP20160520T1 (Direct) |
| HU (1) | HUE027982T2 (Direct) |
| IL (1) | IL203926A (Direct) |
| MX (1) | MX2010002295A (Direct) |
| PL (1) | PL2201018T3 (Direct) |
| SI (1) | SI2201018T1 (Direct) |
| TW (1) | TWI437988B (Direct) |
| WO (1) | WO2009038757A2 (Direct) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820657B2 (en) | 2006-03-17 | 2010-10-26 | Ambit Biosciences Corporation | Imidazolothiazole compounds for the treatment of disease |
| SI2201018T1 (sl) | 2007-09-19 | 2016-09-30 | Ambit Biosciences Corporation | Trdne oblike, ki obsegajo N-(5-terc.butil-izoksazol-3-il)-N'-(4-Y7-(2- morfolin-4-il-etoksi)imidazoY2,1-B"Y 1,3"benzotiazol-2-ilfenil)sečnina, njihove sestave in uporabe z njimi |
| EP2596795A1 (en) * | 2007-11-08 | 2013-05-29 | Ambit Biosciences Corporation | Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| ES2681529T3 (es) | 2009-03-23 | 2018-09-13 | Ambit Biosciences Corporation | Métodos de tratamiento utilizando terapia de combinación |
| SMT202000092T1 (it) | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| WO2011056764A1 (en) | 2009-11-05 | 2011-05-12 | Ambit Biosciences Corp. | Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles |
| EP2496584B1 (en) * | 2009-11-05 | 2016-09-21 | Ambit Biosciences Corporation | Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives |
| CN103172648B (zh) * | 2011-12-20 | 2016-05-25 | 上海迪诺医药科技有限公司 | 三杂环衍生物、制备方法及应用 |
| JP6116847B2 (ja) | 2012-10-01 | 2017-04-19 | アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | シクロデキストリンとの混合体を含有する錠剤 |
| CN104513257B (zh) * | 2013-09-26 | 2017-02-15 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| WO2016133194A1 (ja) | 2015-02-20 | 2016-08-25 | 第一三共株式会社 | がんの併用治療法 |
| CN109251181B (zh) * | 2017-07-13 | 2021-08-31 | 广东东阳光药业有限公司 | 取代脲衍生物的盐及其在药物中的应用 |
| AU2018304177B2 (en) * | 2017-07-18 | 2023-11-02 | Basf Se | Methods for the purification of L-glufosinate |
| CN110763544A (zh) * | 2019-09-20 | 2020-02-07 | 南京聚谱检测科技有限公司 | 一种激光剥蚀样品制靶用快干可精磨粘合剂 |
| CN111413421A (zh) * | 2020-02-20 | 2020-07-14 | 广东电科院能源技术有限责任公司 | 污泥燃烧后灰尘中氯离子含量的测试方法、控制方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL129432C (Direct) | 1964-02-29 | |||
| NL129626C (Direct) | 1964-04-08 | |||
| US3210370A (en) | 1964-06-22 | 1965-10-05 | Upjohn Co | Process for preparing 2, 2'-methylene-bisareneimiazoles |
| FR2463774A1 (fr) | 1979-08-21 | 1981-02-27 | Yamanouchi Pharma Co Ltd | Derives du 2-phenylimidazo(2,1-b)benzothiazole |
| US4354970A (en) | 1980-03-07 | 1982-10-19 | Eastman Kodak Company | Indoline coupled isothiazole azo dyes |
| JPS56138196A (en) | 1980-03-29 | 1981-10-28 | Yamanouchi Pharmaceut Co Ltd | Imidazo (2,1-b)benzothiazole derivative |
| JPS5740492A (en) | 1980-08-22 | 1982-03-06 | Yamanouchi Pharmaceut Co Ltd | Novel 2-phenylimidazo 2,1-b benzothiazole derivative |
| JPS57149288A (en) | 1981-03-12 | 1982-09-14 | Yamanouchi Pharmaceut Co Ltd | Imidazo(2,1-b)benzothiazole derivative |
| JPS58109491A (ja) * | 1981-12-23 | 1983-06-29 | Yamanouchi Pharmaceut Co Ltd | ２−フエニルイミダゾ〃２，１−ｂ「あ」ベンゾチアゾ−ル誘導体 |
| US4464384A (en) | 1981-12-23 | 1984-08-07 | Yamanouchi Pharmaceutical Co., Ltd. | 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| US4880824A (en) | 1987-09-21 | 1989-11-14 | Ortho Pharmaceutical Corporation | Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers |
| EP0524055A1 (fr) | 1991-07-19 | 1993-01-20 | Synthelabo | Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique |
| JPH05107705A (ja) | 1991-10-17 | 1993-04-30 | Konica Corp | 新規な写真用カプラー |
| DK0571253T3 (da) | 1992-05-19 | 1999-07-19 | Adir | Benzimidazolderivater med antidiabetisk og antiblodpladekoagulerende virkning |
| FR2699920B1 (fr) | 1992-12-24 | 1995-02-10 | Synthelabo | Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique. |
| EP0607076A1 (fr) | 1993-01-15 | 1994-07-20 | Synthelabo | Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA |
| FR2700546B1 (fr) | 1993-01-15 | 1995-02-17 | Synthelabo | Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique. |
| JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔２，１−ｂ〕チアゾール誘導体 |
| FR2722501B1 (fr) | 1994-07-13 | 1996-08-09 | Synthelabo | Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique |
| JP3178843B2 (ja) | 1995-03-13 | 2001-06-25 | 日研化学株式会社 | イミダゾチアゾール化合物 |
| AU3783497A (en) | 1996-08-09 | 1998-03-06 | Yamanouchi Pharmaceutical Co., Ltd. | Metabotropic glutamate receptor agonists |
| US6127387A (en) | 1996-12-10 | 2000-10-03 | Thomas Jefferson University | Use of CD4-binding small molecules to inhibit immune responses |
| FR2759698B1 (fr) | 1997-02-20 | 1999-03-19 | Synthelabo | Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique |
| JPH11106340A (ja) | 1997-10-02 | 1999-04-20 | Sumitomo Pharmaceut Co Ltd | Ｓｔａｔ６活性化阻害剤 |
| CA2315717C (en) | 1997-12-22 | 2011-02-01 | Bayer Corporation | Inhibition of raf kinase using substituted heterocyclic ureas |
| DE19805117A1 (de) | 1998-02-09 | 1999-08-12 | Bayer Ag | Neue Oxazolidinone mit azolhaltigen Tricyclen |
| DE19905278A1 (de) | 1999-02-09 | 2000-08-10 | Bayer Ag | Oxazolidinone und ihre Verwendung als antibakterielle Mittel |
| GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
| JP2001048786A (ja) | 1999-08-05 | 2001-02-20 | Yamanouchi Pharmaceut Co Ltd | 三環式ヘテロアリール誘導体 |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP2001192386A (ja) | 1999-10-29 | 2001-07-17 | Meiji Seika Kaisha Ltd | 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤 |
| DE10019714A1 (de) | 2000-04-20 | 2002-01-10 | Gruenenthal Gmbh | Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen |
| AU2001278875B2 (en) | 2000-07-06 | 2007-06-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tetrahydrobenzothiazole analogues as neuroprotective agents |
| US6696441B1 (en) | 2000-08-11 | 2004-02-24 | The Regents Of The University Of California | Inhibition of p53-induced stress response |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| US20030143199A1 (en) | 2001-10-09 | 2003-07-31 | Carson Dennis A. | Use of STAT-6 inhibitors as therapeutic agents |
| US20040127719A1 (en) | 2002-03-08 | 2004-07-01 | Kexin Yang | Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same |
| TW200409746A (en) * | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
| CA2506796A1 (en) | 2002-11-25 | 2004-06-10 | Pharmacia Corporation | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors |
| JP2006516139A (ja) | 2002-12-18 | 2006-06-22 | マリンクロッド・インコーポレイテッド | ヘテロアリールアセトアミド化合物の合成 |
| KR100647583B1 (ko) | 2003-10-07 | 2006-11-17 | 삼성에스디아이 주식회사 | 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자 |
| JP2007512255A (ja) | 2003-11-13 | 2007-05-17 | アンビット バイオサイエンシス コーポレーション | キナーゼ調節因子としての尿素誘導体 |
| US7820657B2 (en) * | 2006-03-17 | 2010-10-26 | Ambit Biosciences Corporation | Imidazolothiazole compounds for the treatment of disease |
| SI2201018T1 (sl) | 2007-09-19 | 2016-09-30 | Ambit Biosciences Corporation | Trdne oblike, ki obsegajo N-(5-terc.butil-izoksazol-3-il)-N'-(4-Y7-(2- morfolin-4-il-etoksi)imidazoY2,1-B"Y 1,3"benzotiazol-2-ilfenil)sečnina, njihove sestave in uporabe z njimi |
| EP2596795A1 (en) | 2007-11-08 | 2013-05-29 | Ambit Biosciences Corporation | Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
-
2008
- 2008-09-19 SI SI200831613A patent/SI2201018T1/sl unknown
- 2008-09-19 AU AU2008302744A patent/AU2008302744B2/en active Active
- 2008-09-19 CN CN2008801167866A patent/CN101868465B/zh active Active
- 2008-09-19 PL PL08832577.4T patent/PL2201018T3/pl unknown
- 2008-09-19 ES ES08832577.4T patent/ES2573292T3/es active Active
- 2008-09-19 DK DK08832577.4T patent/DK2201018T3/en active
- 2008-09-19 KR KR1020107008302A patent/KR101572701B1/ko active Active
- 2008-09-19 CA CA2696776A patent/CA2696776C/en active Active
- 2008-09-19 HU HUE08832577A patent/HUE027982T2/en unknown
- 2008-09-19 MX MX2010002295A patent/MX2010002295A/es active IP Right Grant
- 2008-09-19 JP JP2010525832A patent/JP5462168B2/ja active Active
- 2008-09-19 HR HRP20160520TT patent/HRP20160520T1/hr unknown
- 2008-09-19 US US12/233,906 patent/US8883783B2/en active Active
- 2008-09-19 WO PCT/US2008/010884 patent/WO2009038757A2/en not_active Ceased
- 2008-09-19 AR ARP080104110A patent/AR068528A1/es unknown
- 2008-09-19 BR BRPI0816904A patent/BRPI0816904B8/pt active IP Right Grant
- 2008-09-19 TW TW097136260A patent/TWI437988B/zh active
- 2008-09-19 KR KR1020157023723A patent/KR20150104231A/ko not_active Ceased
- 2008-09-19 EP EP08832577.4A patent/EP2201018B1/en active Active
-
2010
- 2010-02-11 IL IL203926A patent/IL203926A/en active IP Right Grant
-
2014
- 2014-10-07 US US14/508,967 patent/US9585892B2/en active Active
-
2016
- 2016-05-24 CY CY20161100450T patent/CY1117583T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068528A1 (es) | Formas solidas de n-(5-tert-butil-isoxazol-3-il)-n'-(4(7-(2-morfolin-4-il-etoxi) imidazol(2,1-b)(1,3)benzotiazol-2-il)fenil)urea, composiciones con las mismas y usos de los mismos | |
| UY28514A1 (es) | Nuevos compuestos | |
| CL2022003528A1 (es) | Formas cristalinas novedosas (divisional de cl 202002056). | |
| EP3857252A4 (en) | TECHNIQUES TO IMPROVE THE POSITIONING PERFORMANCE OF NEW RADIO (NR) | |
| CO6351782A2 (es) | COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA | |
| CO2018004800A2 (es) | Antagonistas del receptor muscarinico 4 y metodos de uso. | |
| BRPI0412257A (pt) | compostos para inflamação e usos imuno-relacionados | |
| UY28513A1 (es) | Nuevos compuestos | |
| ECSP10010585A (es) | Compuestos de 2- imido- 3- metil pirrolo pirimidinona fenilo- sustituidos como inhibidores bace- 1, composiciones, y su uso | |
| NI200600319A (es) | Antagonistas de ccr2 de sal cuaternaria | |
| ECSP11011284A (es) | Inhibidores de Poli (ADP-ribosa) Polimerasa (PARP) | |
| PA8645301A1 (es) | Anticuerpo anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| AR065083A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
| CY1110746T1 (el) | Ετεροαρωματικες ενωσεις κινολινης και χρηση αυτων ως αναστολεις pde10 | |
| CR9881A (es) | Polimorfos de la sal benzoato de 2-[[6-[(3r)-3amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y metodos de uso para los mismos | |
| JP2009536620A5 (Direct) | ||
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| CR9113A (es) | Compuestos acetamida como fungicidas | |
| AR057237A1 (es) | Metodos y composiciones para actuar sobre la poliubiquitina | |
| EA201000269A1 (ru) | Новые гербициды | |
| ES2570374T3 (es) | Antagonistas del receptor opioide periférico y usos de los mismos | |
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| AR078434A1 (es) | Sales de tetrazol-1-il- fenoximetil-tiazol-2-il- piperinidil- pirimidina sustituida | |
| UY35275A (es) | Derivados de aminopirazina | |
| SV2005002061A (es) | Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |